Radiation Therapy in the Management of Mantle Cell Lymphoma
Fig. 10.1 MCL involving the inferior bulbar conjunctiva of the left eye A careful history and physical examination was performed. The patient had an excellent performance status. He had no…
HEMATOLOGY
Primary CNS Lymphoma
Fig. 8.1 Brain imaging in a 71-year-old woman with PCNSL. (a) Axial CT without contrast reveals a dominant mass in the left frontal lobe. (b) Axial T1 post-contrast image demonstrates…
Primary Testicular Lymphoma
Fig. 9.1 Patient setup in a frog leg for scrotal irradiation Fig. 9.2 Patient setup, skin rendering showing the in tomato colour the edge of the field, the position of…
Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis
Fig. 7.1 Structure of the BCR–ABL1 fusion gene. Panel (a) illustrates the common breakpoints of the BCR and ABL1 genes; panel (b) shows the common transcipt types. The most common BCR–ABL1 transcripts encountered in CML…
Roles for Signaling Molecules in the Growth and Survival of CML Cells
Fig. 3.1 Formation of BCR-AB fusion gene by reciprocal chromosomal translocation t(9;22) and their breakpoints There are several functional domains in BCR-ABL, through which it interacts with downstream signaling molecules…
The Role of New TKIs and Combinations with Interferon-α for the Treatment of CML
Fig. 9.1 Overall cytogenetic and molecular response rates of chronic phase CML to ponatinib within the PACE trial [14]. MCyR states for major cytogenetic response, CCyR for complete cytogenetic response,…
Updated European LeukemiaNet Recommendations for the Management of CML
Disease phase ELN (2006) WHO (2008) ELN (2013) Accelerated phase Blast cells in blood or bone marrow 15–29 %, or blasts + promyelocyte in blood or marrow >30 %, with blasts <30 % Blast cells…
Discontinuation of Therapy and Treatment-Free Remission in CML
Fig. 12.1 Rates of treatment-free remission in the (a) STIM and (b) TWISTER clinical trials. Kaplan-Meier estimates of the proportion of patients free of molecular recurrence after imatinib withdrawal. The…
Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance
Mechanism of resistance Treatment strategies BCR-ABL1-dependent ABL1-kinase domain mutationsa Second-generation TKIs Ponatinib [77, 78] or allosteric inhibitors BCR–ABL1 amplification BCR-ABL1-independent (intrinsic) Activation of downstream signalling JAK-STAT pathway PI3K/AKT/mTOR pathway JAK2…
Safety Profiles of First-Line TKIs and Managing Adverse Effects
Imatinib Nilotinib Dasatinib Bosutinib Ponatinib First line, approved dose 400 mg OD 300 mg BID 100 mg OD NA NA Second line, approved dose 300–400 mg BID 400 mg BID 70 mg BID or 140 mg…
